Quarterly report pursuant to Section 13 or 15(d)

Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.19.1
Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2019
Dec. 31, 2018
Accrued expenses:    
Professional fees $ 1,262 $ 1,434
Salaries, bonuses and related benefits 5,592 5,843
Accrued expenses - related party 16 0
Research and development 4,855 3,805
Research and development - milestones 0 200
Research and development - manufacturing 826 826
Research and development - clinical supplies 215 160
Research and development - license maintenance fees 489 519
Dr. Falk Pharma settlement 300 300
Accrued royalties payable 1,233 1,108
Accrued coupon expense 993 838
Other 4,546 1,327
Total accrued expenses 20,327 16,360
Other long-term liabilities:    
Deferred expenses related to build-out [1] 2,276 5,211
Total other long-term liabilities $ 2,276 $ 5,211
[1] As of March 31, 2019, balance consists of deferred charges related to build-out of the New York facility, and as of December 31, 2018, balance consists of deferred rent and deferred build out charges.